Here, we show that the murine neurodegenerative disease mdf (autosomal recessive mouse mutant 'muscle deficient') is caused by a loss-of-function mutation in Scyl1, disrupting the expression of N-terminal kinase-like protein, an evolutionarily conserved putative component of the nucleocytoplasmic transport machinery. Scyl1 is prominently expressed in neurons, and enriched at central nervous system synapses and neuromuscular junctions. We show that the pathology of mdf comprises cerebellar atrophy, Purkinje cell loss and optic nerve atrophy, and therefore defines a new animal model for neurodegenerative diseases with cerebellar involvement in humans.
INTRODUCTION
So far, several molecular mechanisms associated with specific neurodegenerative disorders have been identified; however, a vast majority of diseases characterized by neuronal degeneration and the resultant disabilities such as muscular atrophy, motor dysfunction and paralysis are still poorly understood. Most of these diseases are fatal and no therapeutic strategies are available. Therefore, identification of new molecules involved in cellular pathways, which are indispensable for neuronal and neuromuscular functional integrity and that could be targeted therapeutically is crucial.
To this end, we investigated the molecular defect underlying the autosomal recessive mouse mutant 'muscle deficient' (mdf ; Womack et al, 1980; Sweet, 1983) . Although several clinical and pathological changes such as progressive neuromuscular atrophy and hindlimb paralysis are compatible with motor neuron disease (Blot et al, 1995) , the mdf mouse also shows phenotypes indicating cerebellar involvement such as gait ataxia, abnormal hindlimb posture and tremor (supplementary Fig 1 and video 1  online) . Therefore, we proposed that mdf can be linked to both motor neuron disease and spinocerebellar ataxia (SCA), thus representing an important model for recessively inherited neurodegenerative disorders in humans.
RESULTS AND DISCUSSION
By using intercross breeding strategies, we confined the mdf locus that had been previously mapped to mouse chromosome 19 A (Sweet, 1983; Poirier et al, 1998) . Among the 48 candidate genes within the approximately 0.9 Mb mdf region, we identified Scyl1 (RefSeq DNA NM_023912.1) as the disease causing gene after we detected an inserted thymidine in exon 8 (Fig 1A) . This mutation fully segregated with the disease phenotype on different genetic backgrounds (supplementary video 2 online) and all parental breeders, as well as approximately 50% of their offspring, were heterozygous carriers. We also found the mutation in an mdf/mdf DNA sample obtained directly from the Jackson Laboratories (Bar Harbor, ME, USA), where the mutant originally arose (Womack By using quantitative mRNA assays, we found that Scyl1 transcripts were markedly reduced in nervous tissues and to a lesser extent in skeletal muscle from Scyl1 mdf/mdf mice, which is indicative of nonsense-mediated mRNA decay (Fig 1C) .
Scyl1 is highly conserved among eukaryotes and contains an amino-terminal serine-threonine kinase-like domain (Liu et al, 2000; Kato et al, 2002) . Further domains, detected by in silico annotation, comprise four HEAT repeats and a secretory carrier membrane protein domain (Fig 1B) , indicating that Scyl1 interacts with other proteins and is involved in intracellular transport processes. To investigate Scyl1 expression and distribution, we raised antibodies against N-and carboxy-terminal peptides. On western blots, both antibodies detected a major immunoreactive band with a molecular weight of approximately 105 kDa, which is in accordance with previously reported migration properties (Liu et al, 2000) , in all probed murine and human tissue extracts. By contrast, the antibodies failed to detect a corresponding band in all tissue extracts from mutant Scyl1 mdf/mdf mice, indicating that the mutation causes a complete loss of full-length Scyl1 protein (supplementary Fig 2A online) . No lower-molecular-weight bands were detected by the antibody against the N terminus in Scyl1 mdf/mdf tissues, indicating the absence of truncated protein products ( Fig 1D) . When we probed brain sections using in situ hybridization, we found prominent Scyl1 expression confined to the neuronal perikarya-most pronounced in the Purkinje cells in the cerebella of normal mice ( Fig 1E) -which is fully compatible with expression patterns shown in the Allen Brain Atlas (Lein et al, 2007) . Scyl1-specific antibodies intensely labelled all central nervous system (CNS) neurons in sections from wild-type mice and humans, whereas no such staining was observed in mutant Scyl1 mdf/mdf CNS tissues (Fig 2A,B) . We found prominent Scyl1 expression in all CNS neurons, including cortical neurons (Fig 2C) , brain-stem neurons ( Fig 2D) and anterior horn spinal cord motor neurons ( Fig 2E) .
In addition to Scyl1 expression throughout CNS neurons and neuronal dendrites (Fig 2C-F) , the protein was also detected in the axons of peripheral nerves (Fig 2H) , indicating axonal transport of Scyl1. In agreement with this hypothesis, we detected Scyl1 accumulation in axonal spheroids ( Fig 2G) : these age-related, neuropathological structures represent sites where axonally transported proteins usually accumulate. Furthermore, we found Scyl1 to be enriched at synapses in the CNS and in the periphery at the neuromuscular junction (Fig 2I) , indicating further that Scyl1 is subjected to axonal transport.
As we detected prominent Scyl1 expression in Purkinje cells of the cerebella of wild-type mice and humans ( Fig 3A,B) , we investigated this cell type more closely in Scyl1-deficient mice and found that many Purkinje cells showed various pathological changes indicative of neuronal degeneration in mdf cerebella ( Fig 3C) . Our observation of basket formations devoid of Purkinje cells ('empty baskets'; inset in Fig 3C) indicates that pre-existing Purkinje cells have disappeared in Scyl1-deficient cerebella. Consistent with this observation, we found that the overall number of Purkinje cells in all areas of Scyl1 mdf/mdf cerebella was markedly reduced (Fig 3D) . As this reduction in Purkinje cells was already pronounced in young mutants (45 days), we propose that loss of Purkinje cells represents an early, pre-clinical pathology in Scyl1-deficient mice. Purkinje cell-related pathologies ranging from loss of Purkinje cells to multiple degenerative abnormalities became most clearly visible with Purkinje-cellspecific Calbindin staining (Fig 3E,F) . Dendritic arborization of Purkinje cells was found to be markedly reduced-characterized by paucity of ramification and axonal swellings (inset in Fig 3F) which is compatible with ongoing neurodegeneration. Whole median sagittal cross-sections showed a marked atrophy of the cerebellar vermis in mdf mice (Fig 3G,H) .
Our findings on the cerebellar neuropathology in Scyl1-deficient mice suggest that the loss of Purkinje cells in mdf is an early-onset and progressive degenerative condition associated with atrophy rather than a developmental defect in the formation of the Purkinje cell layer. We have therefore unraveled a series of clinical and pathological findings in mdf, which are characteristic of SCA in humans and corresponding mouse models. This prompted us to investigate the optic nerve of mdf animals more closely, because optic atrophy represents a pathology common to several types of SCAs. Indeed, we found that Scyl1 mdf/mdf optic nerve cross-sections from comparable retrobulbar regions had visibly smaller diameters when compared with wild-type samples (supplementary Fig 3A online ). Morphometric analysis based on electron micrographs of ultrathin cross-sections from optic nerves showed a significantly increased proportion of small-diameter myelinated fibres and thinner myelin sheaths in 2-year-old Scyl1 mdf/mdf mice compared with wild-type animals, compatible with hypomyelination and axonal degeneration (supplementary Fig  3B online) . Recently, an autosomal recessive disorder, characterized by spastic paraplegia, optic atrophy and neuropathy (SPOAN), has been mapped to human chromosome 11q13, a region encompassing the human Scyl1 orthologue (Macedo-Souza et al, 2005) . To test whether SPOAN represents the human mdf disease counterpart, we sequenced the entire SCYL1 gene of two representative patients of two SPOAN families. However, we did not find any mutation, excluding SPOAN as the human disease counterpart.
In our study, Scyl1 emerged as a new protein essential for neuronal and, particularly, Purkinje cell survival, the disruption of which causes an early-onset and progressive neurodegenerative disorder. Intriguingly, recent evidence from a protein-protein interactome for human inherited diseases characterized by degeneration of Purkinje cells, developed by Lim et al (2006) , readily supports the relevance of Scyl1 in the context of human neurodegenerative disorders: the human SCYL1-encoded protein was found to interact with the Coilin protein (COIL), which is also a binding partner for ataxin 1 (which causes SCA1), puratrophin 1 (implicated in degeneration of Purkinje cells) and Survival motor neuron protein (SMN; the loss of which causes spinal muscular atrophy). This established SCYL1 as a member of the 'ataxia-ome' -the protein-protein interaction network for human ataxias and disorders of Purkinje cell degeneration (Humbert & Saudou, 2006; Lim et al, 2006) . Together with our findings, this classifies SCYL1 as a putative candidate gene for human neurodegenerative diseases involving the cerebellum.
As for many proteins associated with disease, the precise cellular function of Scyl1 and its role in pathogenesis of neuronal 
arrows). (H) Strong axoplasmic
Scyl1-specific staining of an intramuscular nerve branch in wild-type skeletal muscle (skm; arrowheads in inset). Scyl1 reactivity of a neuromuscular junction (NMJ) is indicated (arrow). (I) Scyl1 distribution at a wild-type NMJ: pronounced labelling of presynaptic terminal axons (arrows) and weaker reactivity of the post-synaptic sarcoplasm (arrowhead). a-Bungarotoxin (BgTx, arrowhead) was used as a postsynaptic marker. Confocal overlay of Scyl1 immunosignals (green) with BgTx-specific red fluorescence shows predominant presynaptic Scyl1 expression, which was not detectable at NMJs in Scyl1 mdf/mdf mice (lower panel). All immunostainings shown were performed using the antibody raised against the Scyl1 C terminus. is supported further by reported interactions with the nuclear pore protein NUP98 and the nuclear export receptor exportin-7 (XPO7). Therefore, we propose that Scyl1 defciency in neurons might cause degeneration owing to a defect in the nucleocytoplasmic transport machinery, a new pathway involved in neurodegeneration.
METHODS
Animals used in this study. We obtained mdf mice (B6C3Fe a/a-mdf/J) from the Jackson Laboratory (Bar Harbor, ME, USA), where mdf originally emerged as a spontaneous autosomal recessive mutant in a C57BL/6J-ln fz stock (Womack et al, 1980) . Mice stocks were maintained at the Division of Laboratory Animal Science and Genetics (Medical University Vienna, Himberg, Lower Austria) following institutionally approved protocols for the humane treatment of animals. Animals were killed by cervical dislocation. Genetic mapping and high-throughput sequencing. We generated an intercross by breeding B6C3Fe-mdf-mice with SJL mice. Fine mapping was carried out by PCR for markers D19Mit32, D19Mit68, D19Mit59, D19Mit109 and D19Mit126. Corresponding PCR fragments were generated from 123 mdf/mdf mice (correlating to 246 meioses) by standard PCR, using fluorescencelabelled primers. PCR products were separated in an ABI3100 DNA sequencer (Applied Biosystems, Foster City, CA, USA) and subsequently analysed with the GenScan and Genotyper Software (Applied Biosystems). Primers for all coding exons of the 48 candidate genes located in the critical interval were designed using Exon Locator and eXtractor (http://variation.swmed.edu/ex_lax/elxrdb_query.html), allowing amplification of all fragments under the same PCR conditions. PCR products were purified using 96-well filter plates (Millipore, Billerica, MA, USA) on a Miniprep robot (TECAN, Crailsheim, Germany). The fragments were sequenced using BigDye Version 3.1 (Applied Biosystems), according to the manufacturer's recommendations. Sequences were purified using the 96-well filter plates (Millipore), using the Miniprep robot and separated in an ABI3730 sequencer (Applied Biosystems). Sequence traces were then analysed using the SeqMan software (DNASTAR, Madison, WI, USA). Scyl1 genotyping. After identification of the Scyl1 mutation, the single-nucleotide insertion was genotyped by a PCR assay using allele-specific primers. After subjecting mouse tail-tip DNA to PCR amplification, the respective genotypes were deduced from banding patterns after electrophoretic separation of reaction products on polyacrylamide gels and visualization by fluorescence scanning (Typhoon; GE Healthcare, Chalfont St Giles, UK). In situ hybridization. Cryosections (10 mm) of wild-type mouse brains were probed for Scyl1-specific probes. A 475 bp complementary DNA reverse transcription-PCR (RT-PCR) product was generated with primers 5 0 -AGCCAGCTGAGAAGCAGAAG-3 0 , and 5 0 -ATAGGACCCTGGTCGTCCTT-3 0 , and subsequently inserted into the pCR II TOPO Vector (Invitrogen, Carlsbad, CA, USA). Templates for antisense and sense probes were generated by digesting the plasmid with ApaI and KpnI, respectively. RNA probes were generated using the RNA labelling Kit (Roche Diagnostics, Mannheim, Germany), in the presence of digoxigenin (DIG)-labelled UTP. Slides were fixed, dehydrated, hybridized overnight at 37 1C, thoroughly washed, dehydrated and stained with DIG antibody (Roche) and NBT-BCIP (nitro-blue tetrazolium chloride and 5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt). Quantitative real-time PCR. Total RNA was extracted from muscle and brain tissue of Scyl1 þ / þ and Scyl1 mdf/mdf mice, respectively, and transcribed into cDNA by SuperScript II Reverse Transcriptase (Invitrogen) using random hexamer oligonucleotides. To quantify the amount of Scyl1 mRNA, we used a real-time RT-PCR assay based on TaqMan technology, involving separate amplification of Scyl1 and an internal reference, b-2-microglobulin (B2m), using commercial Taqman probes (Applied Biosystems; assays-on-demand: Scyl1-Mm00452459_m1; B2m-Mm00437762_m1). Quadruple measurement of each cDNA was calculated. The amount of Scyl1 mRNA was calculated using the comparative C t method (DDC t ) as described previously (Thiel et al, 2003) . Generation of polyclonal antibodies. Two polyclonal antibodies were directed against the unique mouse amino-acid sequences MWFFARDPVRDFPFEL or KGPMKLGARKLD, present either at the N terminus (aa 1-16, Scyl1-N) or at the C terminus (aa 795-806; Scyl1-C) of Scyl1. Peptides were synthesized with terminal cysteine residues, conjugated to the carrier protein keyhole limpet haemocyanin and purified by a commercial laboratory (Gramsch Laboratories, Schwabhausen, Germany). Antibodies from rabbit antisera were purified by affinity chromatography using the corresponding peptides coupled to thiopropyl sepharose 6B (GE Healthcare). Antibody specificity was established by pre-adsorption of the antibodies with their cognate peptide antigens, which completely abolished immunoreactivity (supplementary Fig 2B,C online) . Owing to high homology, both antibodies recognize human SCYL1 and are predicted to crossreact with the rat homologue of Scyl1. SDS-polyacrylamide gel electrophoresis and western blots. Tissue extracts were prepared by disruption in lysis buffer (120 mM Tris (pH 6.8), 200 mM dithiothreitol, 4% SDS, 20% glycerol) and separated on 6-12% polyacrylamide Tris-glycine SDS gels, and electrotransferred onto polyvinylidene difluoride or nitrocellulose membranes (Hybond, GE Healthcare). Equal loading of total protein was ascertained by electrophoresis of extracts on separate gels stained with Coomassie blue and densitometric analysis using the ImageJ software package. Detection was carried out with AP-conjugated secondary antibodies (1:1,000) and NBT-BCIP. Scyl1 antibodies were used at 1:800 dilution (Scyl1-C) or 1:200 (Scyl1-N). Histology and immunohistochemistry. After dissection, tissues were snap-frozen in dry ice-cooled 2-methylbutane. Tissue samples were stored at À80 1C and cut on a cryostat. Cryosections were stained with haematoxylin and eosin (H&E). For paraffinembedded histology, tissues were fixed in 3.7% paraformaldehyde, embedded in paraffin and subsequently processed for respective histological analyses.
Purkinje cell counts were taken by two independent, blinded investigators on the basis of H&E-stained cerebellar sections from age-matched wild-type and mdf-mutant mice. To account for variant Purkinje cell densities in different folia, a series of representative images were obtained (nX25). Images were analysed using ImageJ and Purkinje cells were counted on segmented lines and adjusted to an arbitrary length unit. Statistical analysis using the Kruskal-Wallis rank sum test and boxplots were prepared with the statistical software package R (http://www.r-project.org).
Bielschowsky's silver impregnation method was carried out by treating formalin-fixed paraffin-embedded sections with silver nitrate, followed by reduction to visible metallic silver. For immunohistochemistry, 10 mm cryosections were fixed using 3.7% paraformaldehyde (room temperature, 20 min), rinsed in PBS and subsequently incubated with polyclonal rabbit Scyl1-Cantibody (1:500) or goat Calbindin D-28K antibody (Sigma, St Louis, MI, USA). Secondary antibodies were conjugated to Alexa Fluor 488, Alexa Fluor 594 (Molecular Probes and Invitrogen, Eugene, OR, USA) or to horseradish peroxidase, respectively. Neuromuscular junctions were detected by a-Bungarotoxin conjugated with Alexa Fluor 594 (Molecular Probes). Immunostained sections were analysed using a confocal laser scanning microscope (Fluoview; Olympus, Tokyo). Electron microscopy and morphometric analysis. Animals were transcardially perfused with 4% paraformaldehyde/1% cacodylate buffer and dissected brain tissue was fixed in cacodylate-buffered glutaraldehyde, embedded in epoxy resin and processed for transmission electron microscopy. Optic nerve images were analysed with ImageJ and myelin sheath thickness and g-ratios using outer and inner diameters were calculated from feret diameters. Supplementary information is available at EMBO reports online (http://www.emboreports.org).
